This document describes the 1- alkyl of Formulas I, the He Cheng Lu Line and therapeutical uses of 2- acylglycerol derivative: the cell concentration for the ethanolamine plasmalogens that 1- alkyl, the 2- acylglycerol derivative of the Formulas I cause specific sn-2 to replace when applying what mammalian biological system increases, and does not depend on the ether lipid synthesis ability of system described in what. Raised level can lead to the reduction of the decline of Membrane cholesterol level and amyloid secretion to the type that specific sn-2 replaces by this method. These compounds can be treated or prevented and the horizontal relevant senile disease of the plasmalogen of increased Membrane cholesterol, increased amyloid and reduction with what, such as neurodegeneration (including Alzheimer disease, Parkinson's disease and age-dependent macular degeneration), cognitive impairment, dementia, cancer (for example, prostate cancer, lung cancer, breast cancer, oophoroma and kidney), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).本文描述了式I的1-烷基、2-酰基甘油衍生物的合成路綫和治療用途：當施用於哺乳動物生物系統時所述式I的1-烷基、2-酰基甘油衍生物導致特異性sn-2取代的乙醇胺縮醛磷脂的細胞濃度增加，其不依賴於所述系統的醚脂質合成能力。特異性sn-2取代的種類以此方式升高的水平可以導致膜膽固醇水平下降和澱粉狀蛋白分泌的減少。這些化合物可以用於治療或預防與增加的膜膽固醇、增加的澱粉狀蛋白和減少的縮醛磷脂水平相關的衰老性疾病，諸如神經變性（包括阿爾茨海默病，帕金森病和年齡相關的黃斑變性）、認知損害、癡呆、癌症（例如，前列腺癌、肺癌、乳腺癌、卵巢癌和腎癌）、骨質疏鬆症、雙相性精神障礙和血管疾病（諸如動脈粥樣硬化、高膽固醇血症）。
